TY - JOUR
T1 - Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier
AU - Wong, Ka Hong
AU - Riaz, Muhammad Kashif
AU - Xie, Yuning
AU - Zhang, Xue
AU - Liu, Qiang
AU - Chen, Huoji
AU - Bian, Zhaoxiang
AU - Chen, Xiaoyu
AU - Lu, Aiping
AU - Yang, Zhijun
N1 - Funding Information:
This work was supported by the Hong Kong Baptist University Special Development Fund (SDF18-0319-P03), and Faculty Research Grant (FRG2/16-17/073 and FRG2/15-16/078), grant of the Science and Technology Planning Project of Guangdong Province (2017A050506027) and grant of the Science and Technology Program of Guangzhou (201807010053).
Publisher copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2019/1/17
Y1 - 2019/1/17
N2 - Effective therapy for Alzheimer’s disease is a major challenge in the pharmaceutical sciences. There are six FDA approved drugs (e.g., donepezil, memantine) that show some effectiveness; however, they only relieve symptoms. Two factors hamper research. First, the cause of Alzheimer’s disease is not fully understood. Second, the blood-brain barrier restricts drug efficacy. This review summarized current knowledge relevant to both of these factors. First, we reviewed the pathophysiology of Alzheimer’s disease. Next, we reviewed the structural and biological properties of the blood-brain barrier. We then described the most promising drug delivery systems that have been developed in recent years; these include polymeric nanoparticles, liposomes, metallic nanoparticles and cyclodextrins. Overall, we aim to provide ideas and clues to design effective drug delivery systems for penetrating the blood-brain barrier to treat Alzheimer’s disease.
AB - Effective therapy for Alzheimer’s disease is a major challenge in the pharmaceutical sciences. There are six FDA approved drugs (e.g., donepezil, memantine) that show some effectiveness; however, they only relieve symptoms. Two factors hamper research. First, the cause of Alzheimer’s disease is not fully understood. Second, the blood-brain barrier restricts drug efficacy. This review summarized current knowledge relevant to both of these factors. First, we reviewed the pathophysiology of Alzheimer’s disease. Next, we reviewed the structural and biological properties of the blood-brain barrier. We then described the most promising drug delivery systems that have been developed in recent years; these include polymeric nanoparticles, liposomes, metallic nanoparticles and cyclodextrins. Overall, we aim to provide ideas and clues to design effective drug delivery systems for penetrating the blood-brain barrier to treat Alzheimer’s disease.
KW - Alzheimer’s disease
KW - Blood-brain barrier
KW - Brain delivery
KW - Cell-penetrating peptide
KW - Central nervous system
KW - Nanomaterials
UR - http://www.scopus.com/inward/record.url?scp=85060126129&partnerID=8YFLogxK
U2 - 10.3390/ijms20020381
DO - 10.3390/ijms20020381
M3 - Review article
C2 - 30658419
AN - SCOPUS:85060126129
SN - 1661-6596
VL - 20
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 2
M1 - 381
ER -
